Madrigal Pharmaceuticals (MDGL) Payables (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Payables of $34.5 million for Q2 2026, down 9.11% year-over-year from $38.0 million in Q2 2025, and down 43.23% quarter-over-quarter from $60.8 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Payables (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Payables for 17 consecutive years, with $34.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Payables fell 9.11% year-over-year to $34.5 million; the TTM figure through Jun 2026 stood at $34.5 million (down 9.11% YoY), while the FY2025 annual figure was $48.9 million, up 12.11% from the prior year.
- Payables retreated to $34.5 million in Q2 2026 per MDGL's latest filing, from $60.8 million in the prior quarter.
- Across five years, Payables topped out at $60.8 million in Q1 2026 and bottomed at $9.0 million in Q2 2024.
- Historically, Payables has averaged $30.0 million across 5 years, with a median of $25.9 million in 2022.
- Annual changes were most pronounced in 2022 — Payables surged 958.48% — and 2024, when it tumbled 48.71%.
- Madrigal Pharmaceuticals' Payables stood at $23.8 million in 2022, then climbed by 17.67% to $28.0 million in 2023, then surged by 55.48% to $43.6 million in 2024, then climbed by 12.11% to $48.9 million in 2025, then decreased by 29.39% to $34.5 million in 2026.
- Business Quant data shows MDGL's Payables at $34.5 million in Q2 2026, $60.8 million in Q1 2026, and $48.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 34.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.51 Mn |
| Mar 31, 2026 | 60.80 Mn |
| Dec 31, 2025 | 48.88 Mn |
| Sep 30, 2025 | 44.94 Mn |
| Jun 30, 2025 | 37.98 Mn |
| Mar 31, 2025 | 42.06 Mn |
| Dec 31, 2024 | 43.60 Mn |
| Sep 30, 2024 | 45.97 Mn |
| Jun 30, 2024 | 8.99 Mn |
| Mar 31, 2024 | 21.53 Mn |
| Dec 31, 2023 | 28.04 Mn |
| Sep 30, 2023 | 16.54 Mn |
| Jun 30, 2023 | 17.53 Mn |
| Mar 31, 2023 | 12.13 Mn |
| Dec 31, 2022 | 23.83 Mn |
| Sep 30, 2022 | 18.56 Mn |
| Jun 30, 2022 | 11.29 Mn |
| Mar 31, 2022 | 22.78 Mn |
| Dec 31, 2021 | 21.38 Mn |
| Sep 30, 2021 | 10.42 Mn |